NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine

• NRx Pharmaceuticals received FDA approval for preservative-free ketamine ahead of the November 10, 2026, target date.
• Commercial supply is on hand for labeling and distribution to US hospitals and clinics amid an ongoing ketamine shortage.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300700PRIMZONEFULLFEED9856696) on October 30, 2026, and is solely responsible for the information contained therein.